Contact Us
Drug Search Results
More Filters [+]

LB-100

Alternative Names: lb-100, lb100, lb 100
Latest Update: 2024-06-29
Latest Update Note: Clinical Trial Update

Product Description

Upon injection, PP2A inhibitor LB-100 inhibits the removal of phosphate groups from proteins essential for cell cycle progression. When used with radio- or chemotherapy treatment, this agent prevents the activation of PP2A-mediated repair mechanisms and allows for malignant cells to progress through the cell cycle without having their damaged DNA repaired.

Mechanisms of Action: WEE1 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: LIXTE
Company Location: EAST SETAUKET NY 11733
Company CEO: John S. Kovach
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for LB-100

Countries in Clinic: United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Fibrosarcoma|Leiomyosarcoma|Liposarcoma, Myxoid|Myelodysplastic Syndrome|Preleukemia|Synovial Sarcoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
ENHANCER

P2

Active, not recruiting

Leiomyosarcoma|Fibrosarcoma|Liposarcoma, Myxoid|Synovial Sarcoma

2024-12-20

MCC-19635

P2

Recruiting

Preleukemia|Myelodysplastic Syndrome

2021-05-01

23%

Recent News Events

Date

Type

Title

08/15/2024

News Article

 LIXTE Biotechnology Holdings to Present at Two Investor Conferences

06/14/2024

News Article

 LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial

06/14/2024

News Article

 LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial

06/06/2024

News Article

 Scientific Journal Reports Findings that Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System

05/10/2024

PubMed

 Enhancing oncogenic signaling to kill cancer cells.

05/01/2024

PubMed

 The phosphatase inhibitor LB-100 creates neoantigens in colon cancer cells through perturbation of mRNA splicing.

03/11/2024

PubMed

 Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions